Clinical trial · Observational
Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
Role of Sclerostin in Mastocytosis Bone Disease
NCT06440148CI-TRIAL-00077667recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues. Bones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bones | — | UNRESOLVED | — |
| Mastocytosis | Mastocytosis | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SCLEROSTIN | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- plasma sclerostin measurements (in pmol/l) SOST gene expression by Real-Time PCR dimensions of osteolytic lesions on low-dose computed tomography (in mm) dimensions of osteosclerotic lesions on low-dose computed tomography (in mm)
- timeFrame
- 1 year
- description
- The Primary Outcome Measures concern: * the measurements of plasma levels of sclerostin and its bioactive form in patients with mastocytosis and healthy volunteers * the measurements of levels of sclerostin and its bioactive form in HMC-1.2 human mast cells unstimulated and stimutaled with Il-6
- measure
- dimensions of osteolytic lesions (in mm)
- timeFrame
- 1 year
- description
- The Primary Outcome Measures concern: \- the measurements of the dimensions of osteolytic bone lesions on low-dose computed tomography in patients with mastocytosis
- measure
- dimensions of osteosclerotic lesions (in mm)
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * Mastocytosis defined according to WHO criteria * Known KIT mutation status Exclusion Criteria: * History of organ transplant * Inability to give informed consent * Pregnancy, Breastfeeding * Vulnerable Patient, defined as: patient with another uncontrolled severe disease; patient under juridical protection
References
Publications (0)
Data not yet available
No reference posted for this study.